	Application No.	Applicant(s)
Notice of Allowability	09/147,443	MORELL ET AL.
	Examiner	Art Unit
	F. Pierre VanderVegt	1644
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>papers filed November 2, 2005</u> .		
2. The allowed claim(s) is/are 22,23,25-33 and 45.		
 Acknowledgment is made of a claim for foreign priority ure a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received:	been received. been received in Application No	
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892)	5. □ Notice of Informal F	Patent Application (PTO-152)
2. \square Notice of Draftperson's Patent Drawing Review (PTO-948)	6. X Interview Summary	
Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date	Paper No./Mail Da 08), 7. ⊠ Examiner's Amendr	
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. Examiner's Statemo	ent of Reasons for Allowance

Application/Control Number: 09/147,443

Art Unit: 1644

EXAMINER'S AMENDMENT

1. An extension of time under 37 CFR 1.136(a) is required in order to make an examiner's amendment that places this application in condition for allowance. During a telephone conversation conducted on November 28, 2005, Timothy Spaulding requested an extension of time for 1 MONTH(S) and authorized the Director to charge Deposit Account No. 19-0741 the required fee of \$120.00 for this extension and authorized the following examiner's amendment. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

IN THE CLAIMS:

Claim 44, drawn to an invention non-elected without traverse in the reply filed October 22, 2003, has been canceled without prejudice or disclaimer.

In claim 29, line 1, the recitation of "pharmaceutical" has been deleted.

In claim 29, line 2, the phrase -- and a pharmaceutically acceptable carrier-- has been added at the end of the claim.

In claim 30, line 1, the recitation of "pharmaceutical" has been deleted.

In claim 30, line 2, the term "immunoglobulin" has been replaced by --polypeptide--.

In claim 30, line 2, the phrase -- and a pharmaceutically acceptable carrier-- has been added at the end of the claim.

In claim 32, line 2, the term "immunoglobulin" has been replaced by --polypeptide--.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to F. Pierre VanderVegt whose telephone number is (571) 272-0852. The examiner can normally be reached on M-Th 6:30-4:00 and Alternate Fridays 6:30-3:00.

Art Unit: 1644

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

F. Pierre VanderVegt, Ph.D. W

Patent Examiner November 28, 2005

SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600